Identify Clinical Protein Therapeutic Lead Candidate

Today, gene display libraries are powerful tools for identifying high-quality clinical protein therapeutic lead candidates; however, significant challenges remain for the full development of the lead candidates. When protein leads have been selected using phage, bacteria, yeast, or cell-free systems and are subsequently expressed in mammalian systems, incorrect protein folding, aggregation or aberrant posttranslational modifications can occur, resulting in a change or a loss of efficacy.

Additionally, genes selected in these non-mammalian systems do not always express well in mammalian cell lines, such as Chinese Hamster Ovary (CHO) cells. Selexis pioneered the SURE Variant Screening™ service to overcome many of these issues by developing an alternative screening paradigm that allows for earlier efficacy assessments of mammalian cell-produced potential clinical lead candidates, by stably expressing the lead molecules directly in CHO cells. This paradigm also eliminates the needs for transient expression platforms and allows for the rapid selection of a final manufacturing cell line.

Leave a Reply